



**Report Number:** 22-001043/D004.R000

**Report Date:** 02/03/2022 **ORELAP#:** OR100028

**Purchase Order:** 

**Received:** 01/27/22 16:45


Customer: IHC LLC

Product identity: 01020506LIRVAP\_PW

Client/Metrc ID:

**Laboratory ID:** 22-001043-0006

# **Summary**







Customer: IHC LLC

825 NW 16th Ave Portland Oregon 97209

United States of America (USA)

Product identity: 01020506LIRVAP\_PW

Client/Metrc ID: .

Sample Date:

**Laboratory ID:** 22-001043-0006

Evidence of Cooling: No
Temp: 17.5 °C
Relinquished by: Client

**Report Number:** 22-001043/D004.R000

**Report Date:** 02/03/2022 **ORELAP#:** OR100028

**Purchase Order:** 

**Received:** 01/27/22 16:45



THE HEMP COLLECT

# **Sample Results**

Potency	Method J A	OAC 2015 V98	3-6 (mod)	Units %	Batch: 2200974	<b>Analyze:</b> 2/3/22	12:00:00 AM
Analyte		ry LOQ reight	Notes				<ul><li>CBD</li></ul>
CBC	6.04	0.0911					<ul><li>CBG</li></ul>
CBC-A <sup>†</sup>	< LOQ	0.0911					<ul><li>CBC</li></ul>
CBC-Total <sup>†</sup>	6.04	0.171					O CBT
CBD	36.9	0.911					<ul><li>CBDV</li><li>CBE</li></ul>
CBD-A	< LOQ	0.0911					CBN
CBD-Total	36.9	0.991					8-THCV
CBDV <sup>†</sup>	3.67	0.0911					<ul><li>THCV</li></ul>
CBDV-A <sup>†</sup>	< LOQ	0.0911					<ul><li>9-THC</li></ul>
CBDV-Total <sup>†</sup>	3.67	0.170					
CBE <sup>†</sup>	3.61	0.0911					
CBG <sup>†</sup>	13.5	0.0911					
CBG-A <sup>†</sup>	< LOQ	0.0911					
CBG-Total	13.5	0.170					
CBL <sup>†</sup>	< LOQ	0.0911					
CBL-A <sup>†</sup>	< LOQ	0.0911					
CBL-Total <sup>†</sup>	< LOQ	0.171					
CBN	3.35	0.0911					
CBT <sup>†</sup>	4.75	0.0911					
$\Delta 8\text{-THC}^{\dagger}$	< LOQ	0.0911					
Δ8-THCV	1.35	0.0911					
Δ9-THC	0.183	0.0911					
THC-A	< LOQ	0.0911					
THC-Total	0.183	0.171					
THCV <sup>†</sup>	0.476	0.0911					
THCV-A <sup>†</sup>	< LOQ	0.0911					
THCV-Total <sup>†</sup>	0.476	0.170					
Total Cannabinoids <sup>†</sup>	73.8						





**Report Number:** 22-001043/D004.R000

**Report Date:** 02/03/2022 **ORELAP#:** OR100028

**Purchase Order:** 

**Received:** 01/27/22 16:45

These test results are representative of the individual sample selected and submitted by the client.

### **Abbreviations**

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220, CCR title 16-division 42. BCC-section 5723

**Limit(s) of Quantitation (LOQ):** The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

† = Analyte not NELAP accredited.

#### Units of Measure

% = Percentage of sample % wt =  $\mu$ g/g divided by 10,000

Approved Signatory

Derrick Tanner General Manager





**Report Number:** 22-001043/D004.R000

**Report Date:** 02/03/2022 ORELAP#: OR100028

**Purchase Order:** 

01/27/22 16:45 Received:



# Hemp / Cannabis Usable / Extract / Finished Products Chain of Custody Record

Revision: 4.00 Control#: CF023 Rev 02/24/2021 Eff: 03/04/2021 ORELAP ID: OR100028

						А	nalys	is Req	ueste	d				D.C.	Number:	
Company: HHC Contact: Kyle Harook Street: 431 NW Flanders St. City: Portland State: Company Demail Results: dropbox Ph: (61) 608164 Fx Results: Billing (if different): beth@thehel	OF Zip: _		- OR 59 compounds	esticide Multi-Residue – 379 compounds		olvents	Moisture & Water Activity		Vicro: Yeast and Mold	Vicro: E.Coli and Total Coliform	tals	SI		Projec Proj Custom R Report to	t Number: ect Name: eporting: o State M and time: 5	ETRC or Other:  5 Business Day Standard Turnaround  8 Business Day Rush Turnaround*  1 Business Day Rush Turnaround*  *Check for availability
Lab  ID Client Sample Identification	Date	Time	Pesticides	Pesticide	Potency	Residual Solvents	Moisture	Terpenes	Micro: Ye	Micro: E.C	Heavy Metals	Mycotoxins	Other:	Sample Type†	Weight (Units)	Comments/Metrc ID
1 0103LIRVAP200_ST	1/27				X									E		
2 0103LIRVAP200_SG	1/27				Х									E		
3 0103LIRVAP200_OG	1/27				х									E		
4 0103LIRVAP200_SP	1/27				х									E		1
5 0103LIRVAP200_PB	1/27				Х									E		1
6 01020506LIRVAP_PW	1/27				Х									E		
7 01020506LIRVAP_FV	1/27	1	+		Х									E		
8 0107LIRVAP200_OGK	1/27		+	_	Х									E		
75.75	1/27	_	1	-	X	BEN SERVE	_							E		
	1/27	-	+	_	Х	_	_	Х						V		
Relinguished By:	Date	Time			Re	eceived	Bv:			Da	te	Tir	me			Lab Use Only:
Kyle Farook	1/27	4:45				)s	-			1	22	-	45	Evidence Sample in	of cooling:  good conditi	or Defient drop  Yes PTNO - Temp (°C):

†-Sample Type Codes: Vegetation (V); Isolates (S); Extract/Concentrate (C); Tincture/Topical (T); Edible (E); Beverage (B)

Samples submitted to Columbia Laboratories with testing requirements constitute an agreement for services in accordance with the current terms of service associated with this COC. By signing "Relinquished by" you are agreeing to these terms 12423 NE Whitaker Way P: (503) 254-1794 | Fax: (503) 254-1452 Page \_\_\_\_of\_ www.columbialaboratories.com Portland, OR 97230





**Report Number:** 22-001043/D004.R000

02/03/2022 Report Date: ORELAP#: OR100028

**Purchase Order:** 

Received: 01/27/22 16:45

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

Labora	tory Qual	lity Contro	ol Results

J AOAC 2015 V	98-6			Bat	ch ID: 2200974		
Laboratory Con	trol Sample						
Analyte	Result	Spike	Units	% Rec	Limits	Evaluation	Notes
CBDVA	0.192	0.2	%	95.9	85.0 - 115	Acceptable	
CBDV	0.201	0.2	%	100	85.0 - 115	Acceptable	
CBE	0.196	0.2	%	98.2	85.0 - 115	Acceptable	
CBDA	0.213	0.2	%	107	85.0 - 115	Acceptable	
CBGA	0.192	0.2	%	95.8	85.0 - 115	Acceptable	
CBG	0.188	0.2	%	94.2	85.0 - 115	Acceptable	
CBD	0.206	0.2	%	103	85.0 - 115	Acceptable	
THCV	0.185	0.2	%	92.5	85.0 - 115	Acceptable	
d8THCV	0.188	0.2	%	93.8	85.0 - 115	Acceptable	
THCVA	0.189	0.2	%	94.4	85.0 - 115	Acceptable	
CBN	0.207	0.2	%	103	85.0 - 115	Acceptable	
exo-THC	0.176	0.2	%	88.2	85.0 - 115	Acceptable	
d9THC	0.196	0.2	%	98.0	85.0 - 115	Acceptable	
d8THC	0.171	0.2	%	85.6	85.0 - 115	Acceptable	
CBL	0.184	0.2	%	91.8	85.0 - 115	Acceptable	
CBC	0.182	0.2	%	91.1	85.0 - 115	Acceptable	
THCA	0.204	0.2	%	102	85.0 - 115	Acceptable	
CBCA	0.196	0.2	%	97.9	85.0 - 115	Acceptable	
CBLA	0.198	0.2	%	98.9	85.0 - 115	Acceptable	
CBT	0.226	0.2	%	113	85.0 - 115	Acceptable	

#### **Method Blank**

Analyte	Result	LOQ	Units	Limits	Evaluation	Notes
CBDVA	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBDV	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBE	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBDA	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBGA	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBG	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBD	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
THCV	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
d8THCV	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
THCVA	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBN	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
exo-THC	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
d9THC	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
d8THC	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBL	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBC	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
THCA	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBCA	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBLA	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	
CBT	<loq< td=""><td>0.1</td><td>%</td><td>&lt; 0.1</td><td>Acceptable</td><td></td></loq<>	0.1	%	< 0.1	Acceptable	

## **Abbreviations**

ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

## Units of Measure:

% - Percent





**Report Number:** 22-001043/D004.R000

02/03/2022 Report Date: ORELAP#: OR100028

**Purchase Order:** 

Received: 01/27/22 16:45

Revision: 1 Document ID: 7148 Legacy ID: Worksheet Validated 04/20/2021

# **Laboratory Quality Control Results**

J AOAC 2015 \	/98-6				Bato	h ID: 2200974		
Sample Duplic	ate							
Analyte	Result	Org. Result	LOQ	Units	RPD	Limits	Evaluation	Notes
CBDVA	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable	
CBDV	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable	
CBE	0.241	0.230	0.1	%	4.81	< 20	Acceptable	
CBDA	2.30	2.28	0.1	%	0.721	< 20	Acceptable	
CBGA	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable	
CBG	0.232	0.215	0.1	%	7.55	< 20	Acceptable	
CBD	2.58	2.52	0.1	%	2.20	< 20	Acceptable	
THCV	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable	
d8THCV	0.455	0.427	0.1	%	6.43	< 20	Acceptable	
THCVA	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable	
CBN	0.403	0.373	0.1	%	7.70	< 20	Acceptable	
exo-THC	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable	
d9THC	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable	
d8THC	78.1	77.7	0.1	%	0.462	< 20	Acceptable	
CBL	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable	
CBC	0.485	0.477	0.1	%	1.63	< 20	Acceptable	
THCA	0.255	0.245	0.1	%	3.76	< 20	Acceptable	
CBCA	0.249	0.246	0.1	%	0.919	< 20	Acceptable	
CBLA	<loq< td=""><td><loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<></td></loq<>	<loq< td=""><td>0.1</td><td>%</td><td>NA</td><td>&lt; 20</td><td>Acceptable</td><td></td></loq<>	0.1	%	NA	< 20	Acceptable	
CBT	0.586	0.521	0.1	%	11.7	< 20	Acceptable	

#### **Abbreviations**

ND - None Detected at or above MRL RPD - Relative Percent Difference LOQ - Limit of Quantitation

### Units of Measure:

% - Percent





**Report Number:** 22-001043/D004.R000

**Report Date:** 02/03/2022 ORELAP#: OR100028

**Purchase Order:** 

Received: 01/27/22 16:45

## Explanation of QC Flag Comments:

Code	Explanation
Q	Matrix interferences affecting spike or surrogate recoveries.
Q1	Quality control result biased high. Only non-detect samples reported.
Q2	Quality control outside QC limits. Data considered estimate.
Q3	Sample concentration greater than four times the amount spiked.
Q4	Non-homogenous sample matrix, affecting RPD result and/or % recoveries.
Q5	Spike results above calibration curve.
Q6	Quality control outside QC limits. Data acceptable based on remaining QC.
R	Relative percent difference (RPD) outside control limit.
R1	RPD non-calculable, as sample or duplicate results are less than five times the LOQ.
R2	Sample replicates RPD non-calculable, as only one replicate is within the analytical range.
LOQ1	Quantitation level raised due to low sample volume and/or dilution.
LOQ2	Quantitaion level raised due to matrix interference.
В	Analyte detected in method blank, but not in associated samples.
B1	The sample concentration is greater than 5 times the blank concentration.
B2	The sample concentration is less than 5 times the blank concentration.